10.Gladman D, Srand V, Mease P, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005; 64(Supp2): P.115-6.
11.Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010 Feb;70(2):272-7.
12.Mumtaz A GP, Kirby B, Waxman R, Coates LC, Veale D, et al. Development of a
composite disease activity index in psoriatic arthritis. Ann Rheum Dis.2010;69 (suppl 3):115.
13.Mease P.J. Measures of Psoriatic Arthritis. Arthritis Care& Research 2011, S11(63), 64-85.
14.Mease P.J. Psoriatic Arthritis:update on pathophysiology, assessement and management Ann Rheum Dis, 2011,70(suppl):77-84.
15.Mease P.J. Psoriatic Arthritis: pharmacotherapy update. Curr Rheum Rep 2010,12,272-80.
16.Mease P., Antoni C.,Gladman D. et al. Psoriatic Arthritis assessement tools in clinical trials. Ann Rheum Dis 2005,64,Suppl:49-54.
17.Coates L. C., Helliwell P. S. Disease measurement: enthesitis,skine,nails,spine and dactylitis. Best Pract Res Clin Rheumatol 2010,24,659-70.
18.Healy P.J., Helliwell P.S. Measuring clinical enthesitis in Psoriatic Arthritis: assessement of existing measures and development of an instrumeny specific to psoriatic arthritis. Arthritis Rheum 2008,59, 686-91.
19.Garret S., Jenkinson T., Kennedy L. G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.. J. Rheumatol, 1994,.21.2286-91.
20.Gladman D., Inman R., Cook R.J. et al. International spondyloarthritis interobserver reliability exercise:the INSPIRE study. 1. Assessement of spinal measures. J Rheumatol 2007,34, 1733-9.
21.Eder L., Chandran V., Shen H. Et al. Is ASDAS better than BASDAI as a mesuare of disease activity in axial psoriatic arthritis? AnnRheum Dis 2010,69,2160-4.
22.Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
23.Gossec L., Smolen J.S., Gaujoux-Viala C. et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011).
24.Ritchlin C.T., Kavanaugh A., Gladman D.D. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.
25.Scottish Intercollegiate Guidelines Network (SIGN publication no 121. Availiable from URL: http://www.sign.ac.uk. Diagnosis and management of psoriasis and psoriatic arthritsi in adult: a national clinical guideline. October 2010.
26.National Institute for Health and Clinical Excellence (NHS), NICE technology appraisal guidance 199. Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis., August 2010.
27.Salliot C., Dernis E., Lavie F., et al. Diagnosis of peripheral psoriatic arthritis: recommenations for clinical practice, based on data from the literature and experts opinion. Joint Bone Spine 2009, Oct;76(5):532-9.
28.Коротаева Т.В. // Ревматология: Национальное руководство / под. ред. Е.Л Насонова, В.А. Насоновой – М. : ГЭОТАР – Медиа, 2008. – С.355-367.
29.Псориатический артрит / Коротаева Т.В. // Ревматология: Клинические рекомендации / под. ред. акад. Е. Л. Насонова.– 2-е изд., испр. и доп.- М. : ГЭОТАР – Медиа, 2010. – С.297-304.
30.Коротаева Т.В., Насонов Е.Л. Стандарты терапии Псориатического артрита //Научно-практическая ревматология. – 2009. - № 3. - С.29-38
31.Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr. Rheum., 2006,54,2665–73.
32.Chandran V., Schentag C.T., Gladman D. CASPAR criteria are sensitive in early psoriatic arthritis (PsA) and are accurate when applied to patients attending a family practice clinic [abstract]. Ann. Rheum. Dis., 2007,66,suppl II,415.
33.Sieper J., Van der Heijde D., Landewe R. et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann. Rheum. Dis. 2009, 68.784–748.
34.Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-5.
35.Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–41.
36.Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147– 57.
37.Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factorfor acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010;130:962–7.
38.Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic.I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868-72.
39.Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-72.
40.Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203–9.
41.Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011;63:195–202.
42.Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010;146:721–6.
43.Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology (Basel) 2008;217:365–73.
44.Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527–34.
45.Bardazzi F, Balestri R, Baldi E, et al. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol. Ther. 2010;23 Suppl 1:S14–9.
46.Wenqing Li, Jiali Han, Abrar A Qureshi. Obesity and risk of incident psoriatic arthritis in US women ARD Online First, published on May 5, 2012 as 10.1136/annrheumdis- 2011-201273.
47.Cañete J.D., Mease P.. The link between obesity and psoriatic arthritis.ard.bmj.com on August 6, 2012.
48.Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71:1273–7.
49.Elkayam O.,Ophhir J., Brener S., et al. Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int 2000,19(3),77-82.
50.Madland T. M., Bjorkkjaer T., brunborg L. A. et al. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. J Rheumatol 2006,33(2),307-10.
51.Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of conventional and biologic drug therapies for the treatment of psoriatic arthritis: current evidence informing the EULAR recommendations for the management of Psoriatic Arthritis. Ann Rheum Dis. Published online July 28, 2011.
52.Kivitz A.J, Espinoza LR, Sherrer YR, et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum 2007, 37, 164 – 73.
53.Sarzi-Puttini P., Santandrea S., Boccassini L.,et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001, 19 (Suppl 22 ), 17 – 20.
54.Borer J.S., Simon L.S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther 2005, 7 (Suppl 4), 14 – 22.
55.Laine, L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest. Endosc. Clin. N. Am. 6, 489–504 (1996).
56.Gislason, G.H. et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med. 2009,169, 141–149.
57.Pipitоne N., Kingsley G.H., Manzo A., et al. Current concepts and new developments in the treatment of psoriatic arthritis Rheumatology Oxford 2003:42:1138-48.
58.Soriano E., McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. A systematic Review. J Rheum 2006,33,1-7.
59.Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford). 2010;49(7):1367-73.
60.Gottlieb NL, Riskin WG. Complications of local corticosteroid injections. JAMA. 1980;243(15):1547-8.
61.Saviola G, Abdi Ali L, Shams Eddin S, et al. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology (Oxford). 2007;46(6):994-8.
62.Scarpa R., Peluso R., Atteno M. et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis:results of a pilot6-month randomized trial with methotraxate. Clin Rheumatol 2008; 27(7),823-6.
63.Oliveri I., D'Angelo S., Palazzi C. et al. Treatment strategies for early psoriatic arthritis Expert Opin Pharmacother 2009; (2), 271-82.
64.Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PsA) – an analysis of 220 patients. QJ Med 1987, 62, 127–41.
65.McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003,42,778-83.
66.Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995,22, 675-9.
67.Queiro-Silva R, Torre-Alonso JC, Tinturé-Eguren T, López-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003,62,68-70.
68.Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005,64,188-90.
69.Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002; 359: 1173-7.
70.Pathirana D., Ormerod A.D., Saigag P. et al. European S3-guidelines on systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 1-70.
71.Helliwell P.S., Taylor W. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. J. Rheumatol. 2008;
35:472-6.
72.Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008,67,855–859.
73. |
Lie E, Van |
der Heijde D, Uhlig T, et al. Effectiveness and retention rates of |
|
methotrexate |
in psoriatic |
arthritis |
in comparison with methotrexate-treated patients with |
rheumatoid arthritis. Ann Rheum Dis |
2010, 69, 671 – 6. |
||
74.Black RL, O’Brien WM, Vanscott EJ et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964, 189, 743 – 7.
75.Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebocontrolled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum1984, 27, 376 – 8